A Phase 3 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Ertapenem intravenous in Infection, sponsored by Bayer. Completed at 52 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-07.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 804 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed or suspected intra abdominal infection defined as follows:
For a confirmed intra abdominal infection, a surgical procedure (laparotomy or laparoscopy) must have been performed within 24 hours prior to enrollment and reveal at least one of the following:
Subjects enrolled on the basis of a suspected intra abdominal infection must have:
Radiological evidence [abdominal plain films, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound] of gastrointestinal perforation or intra-abdominal abscess and the following signs and symptoms:
At least two of the following SIRS criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
Drug: Moxifloxacin (Avelox, BAY12-8039)
Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
Drug: Ertapenem intravenous
Moxifloxacin, 400mg, administered intravenously once daily
Active treatment: Ertapenem 1.0g, administered intravenously once daily
Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population
Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.
Time frame: 21 to 28 days after completion of study drug therapy
Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population
Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.
Time frame: During treatment at day 5 +/- 1 day
Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)
Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.
Time frame: During treatment at day 5 +/- 1 day
Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population
Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.
Time frame: after 5 - 14 days of therapy
Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)
Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.
Time frame: After 5 - 14 days of therapy
Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)
Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection' - additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.
Time frame: 21 - 28 days after end of therapy
Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)
Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.
Time frame: 21 - 28 days after end of therapy
Number of Subjects Who Died Due to Intra-abdominal Infections
Number of subjects who had died due to intra abdominal infections by the time of TOC visit.
Time frame: 21 - 28 days after end of treatment at TOC Visit
Duration of Hospitalization
Duration of hospitalization in the per protocol population.
Time frame: From the first admission date to the discharge date (from 4 to 71 days after start of study medication)
Duration of Hospitalization Postoperatively
Duration of hospitalization after the first surgery until discharge in the per protocol population.
Time frame: Duration of hospitalization after the first surgery until discharge date (from 4 to 71 days after start of study medication)
Subjects were enrolled from 02 July 2006 to 31 December 2008 at 52 centers in 14 countries: Argentina (9), Belgium (3), Bulgaria (4), Estonia (3), France (2 ), Germany (5), Greece (1), Israel (2), Latvia (6), Lithuania (4), Romania (5), Russia (3), South Africa (3), and Spain (2).
| Milestone | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Started | 410 | 394 |
| End of treatment (eot, day 5 to 14) | 387 | 377 |
| End of study | 360 | 358 |
| Completed | 360 | 358 |
| Not completed | 50 | 36 |
| Withdrew: Adverse event | 10 | 6 |
| Withdrew: Death | 7 | 2 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Lost to follow-up | 27 | 19 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Non compliant with study medication | 0 | 3 |
Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Clinical Cure | 315 | 324 |
| Clinical Failure | 37 | 23 |
Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Clinical Improvement | 210 | 194 |
| Clinical Failure | 0 | 2 |
| Missing | 142 | 151 |
Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Eradication | 5 | 5 |
| Presumed Eradication | 170 | 149 |
| Persistence | 16 | 7 |
| Presumed Persistence | 0 | 2 |
| Superinfections | 0 | 1 |
Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Clinical Cure | 328 | 330 |
| Clinical Failure | 23 | 17 |
| Missing | 1 | 0 |
Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Eradication | 5 | 7 |
| Presumed Eradication | 257 | 247 |
| Persistence | 20 | 9 |
| Presumed Persistence | 13 | 11 |
| Superinfections | 1 | 2 |
| Indeterminate/missing | 1 | 0 |
Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection' - additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Eradication | 0 | 0 |
| Presumed Eradication | 257 | 249 |
| Persistence | 20 | 9 |
| Presumed Persistence | 20 | 18 |
| Superinfections | 0 | 0 |
| Reinfections | 0 | 0 |
Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Clinical Cure | 265 | 254 |
| Clinical Failure | 32 | 22 |
Number of subjects who had died due to intra abdominal infections by the time of TOC visit.
| participants | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Yes | 3 | 1 |
| No | 349 | 346 |
Duration of hospitalization in the per protocol population.
| days | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Duration of Hospitalization | 11.7 ± 7.3 | 11.2 ± 7.8 |
Duration of hospitalization after the first surgery until discharge in the per protocol population.
| days | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Duration of Hospitalization Postoperatively | 11.1 ± 7.1 | 10.7 ± 7.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moxifloxacin (Avelox, BAY12-8039) | — | 60/408 (14.7%) | 115/408 (28.2%) |
| Ertapenem | — | 48/390 (12.3%) | 87/390 (22.3%) |
| Event | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Wound infectionInfections and infestations | 10/408 | 1/390 |
| Cardiac arrestCardiac disorders | 7/408 | 2/390 |
| PneumoniaInfections and infestations | 1/408 | 4/390 |
| Multi-organ failureGeneral disorders | 4/408 | 2/390 |
| Unevaluable eventGeneral disorders | 4/408 | 2/390 |
| Renal failure acuteRenal and urinary disorders | 4/408 | 1/390 |
| Intestinal fistulaGastrointestinal disorders | 1/408 | 3/390 |
| PeritonitisGastrointestinal disorders | 3/408 | 2/390 |
| SepsisInfections and infestations | 3/408 | 1/390 |
| Septic shockInfections and infestations | 3/408 | 0/390 |
| Event | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem |
|---|---|---|
| Wound infectionInfections and infestations | 37/408 | 28/390 |
| NauseaGastrointestinal disorders | 30/408 | 17/390 |
| Lipase increasedInvestigations | 25/408 | 24/390 |
| DiarrhoeaGastrointestinal disorders | 23/408 | 18/390 |
| Age, Continuous(years) | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem | Total |
|---|---|---|---|
| Mean | 48.1 ± 18.3 | 47.0 ± 18.2 | 47.4 ± 18.2 |
| Sex: Female, Male(Participants) | Moxifloxacin (Avelox, BAY12-8039) | Ertapenem | Total |
|---|---|---|---|
| Female | 156 | 131 | 287 |
| Male | 254 | 263 | 517 |
The record gives a start of Jul 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin